Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

Inclusion Criteria: * Age\>=18Y and ≤75Y * Good Organ Function * Expected survival time ≥ 3 months * mCRC that have been diagnosed histologically * KRAS/NRAS/BRAF WT verified by PCR or NGS of tumor tissue * ECOG score 0-1; Exclusion Criteria: * HIV infection * Active clinical severe infection; * A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.